id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-E-3017-0006,FDA,FDA-2019-E-3017,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-01-22T05:00:00Z,2025,1,2025-01-22T05:00:00Z,,2025-01-22T21:01:44Z,,0,0,09000064868ee10c
FDA-2019-E-3017-0005,FDA,FDA-2019-E-3017,Letter to U. S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:13:37Z,,0,0,09000064863656c8
FDA-2019-E-3017-0004,FDA,FDA-2019-E-3017,Determination of Regulatory Review Period for Purposes of Patent Extension; Emgality,Notice,Determinations,2023-12-22T05:00:00Z,2023,12,2023-12-22T05:00:00Z,2024-02-21T04:59:59Z,2023-12-22T14:20:59Z,2023-28233,0,0,0900006486351116
FDA-2019-E-3017-0003,FDA,FDA-2019-E-3017,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2020-03-03T05:00:00Z,2020,3,2020-03-03T05:00:00Z,,2020-03-03T13:35:48Z,,0,0,09000064843d8922
FDA-2019-E-3017-0001,FDA,FDA-2019-E-3017,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2019-06-24T04:00:00Z,2019,6,2019-06-24T04:00:00Z,,2019-06-24T14:39:40Z,,0,0,0900006483d397c8
FDA-2019-E-3017-0002,FDA,FDA-2019-E-3017,Patent Extension Application from Eli Lilly and Company,Other,Application,2019-06-24T04:00:00Z,2019,6,2019-06-24T04:00:00Z,,2019-06-24T14:42:46Z,,0,0,0900006483d397c9